Last reviewed · How we verify
Investigational sIPV
sIPV is an inactivated poliomyelitis vaccine that stimulates immune responses against poliovirus types 1, 2, and 3 to prevent poliomyelitis infection.
sIPV is an inactivated poliomyelitis vaccine that stimulates immune responses against poliovirus types 1, 2, and 3 to prevent poliomyelitis infection. Used for Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3.
At a glance
| Generic name | Investigational sIPV |
|---|---|
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | Inactivated viral vaccine |
| Target | Poliovirus types 1, 2, and 3 |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
As an inactivated poliovirus vaccine, sIPV contains chemically inactivated poliovirus particles that trigger both humoral (antibody) and cellular immune responses without causing disease. The vaccine is designed to provide protection against all three serotypes of poliovirus, preventing paralytic poliomyelitis and contributing to polio eradication efforts.
Approved indications
- Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3
Common side effects
- Injection site pain or swelling
- Fever
- Myalgia
- Fatigue
Key clinical trials
- Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different Manufacturers (PHASE4)
- Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants (PHASE3)
- An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four Doses
- Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine (PHASE3)
- Cross-neutralization Capacity of Immune Serum From Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization (NA)
- Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Phase Ib) (PHASE1, PHASE2)
- Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (PHASE1)
- Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigational sIPV CI brief — competitive landscape report
- Investigational sIPV updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI